IRIS Accounts Production v24.2.0.383 10565653 Board of Directors 1.1.23 31.12.23 31.12.23 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh105656532022-12-31105656532023-12-31105656532023-01-012023-12-31105656532021-12-31105656532022-01-012022-12-31105656532022-12-3110565653ns15:EnglandWales2023-01-012023-12-3110565653ns14:PoundSterling2023-01-012023-12-3110565653ns10:Director12023-01-012023-12-3110565653ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3110565653ns10:SmallEntities2023-01-012023-12-3110565653ns10:AuditExempt-NoAccountantsReport2023-01-012023-12-3110565653ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3110565653ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3110565653ns10:FullAccounts2023-01-012023-12-311056565312023-01-012023-12-3110565653ns10:Director22023-01-012023-12-3110565653ns10:RegisteredOffice2023-01-012023-12-3110565653ns5:CurrentFinancialInstruments2023-12-3110565653ns5:CurrentFinancialInstruments2022-12-3110565653ns5:Non-currentFinancialInstruments2023-12-3110565653ns5:Non-currentFinancialInstruments2022-12-3110565653ns5:ShareCapital2023-12-3110565653ns5:ShareCapital2022-12-3110565653ns5:SharePremium2023-12-3110565653ns5:SharePremium2022-12-3110565653ns5:RetainedEarningsAccumulatedLosses2023-12-3110565653ns5:RetainedEarningsAccumulatedLosses2022-12-3110565653ns5:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3110565653ns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-01-012023-12-3110565653ns5:PlantMachinery2023-01-012023-12-3110565653ns5:IntangibleAssetsOtherThanGoodwill2022-12-3110565653ns5:IntangibleAssetsOtherThanGoodwill2023-12-3110565653ns5:IntangibleAssetsOtherThanGoodwill2022-12-3110565653ns5:FurnitureFittings2022-12-3110565653ns5:ComputerEquipment2022-12-3110565653ns5:FurnitureFittings2023-01-012023-12-3110565653ns5:ComputerEquipment2023-01-012023-12-3110565653ns5:FurnitureFittings2023-12-3110565653ns5:ComputerEquipment2023-12-3110565653ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3110565653ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-31
REGISTERED NUMBER: 10565653 (England and Wales)












OMNIGEN BIODATA LTD

Unaudited Financial Statements

for the Year Ended 31 December 2023






OMNIGEN BIODATA LTD (REGISTERED NUMBER: 10565653)






Contents of the Financial Statements
for the Year Ended 31 December 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


OMNIGEN BIODATA LTD

Company Information
for the Year Ended 31 December 2023







Directors: Dr M S Sandhu
B Ganesan





Registered office: Merlin Place
Milton Road
Cambridge
CB4 0DP





Registered number: 10565653 (England and Wales)





Accountants: Michael Price Associates Ltd
NP-105, iCentre
Howard Way
Newport Pagnell
Milton Keynes
Buckinghamshire
MK16 9PY

OMNIGEN BIODATA LTD (REGISTERED NUMBER: 10565653)

Balance Sheet
31 December 2023

31/12/23 31/12/22
Notes £    £    £    £   
Fixed assets
Intangible assets 4 3,126,957 2,019,485
Tangible assets 5 59,866 25,890
3,186,823 2,045,375

Current assets
Debtors 6 1,012,861 927,222
Cash at bank 221,984 1,107,143
1,234,845 2,034,365
Creditors
Amounts falling due within one year 7 506,847 866,689
Net current assets 727,998 1,167,676
Total assets less current liabilities 3,914,821 3,213,051

Creditors
Amounts falling due after more than one
year

8

(20,833

)

(30,833

)

Provisions for liabilities (11,375 ) -
Net assets 3,882,613 3,182,218

Capital and reserves
Called up share capital 259 249
Share premium 2,081,222 1,676,844
Retained earnings 1,801,132 1,505,125
3,882,613 3,182,218

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

OMNIGEN BIODATA LTD (REGISTERED NUMBER: 10565653)

Balance Sheet - continued
31 December 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 18 September 2024 and were signed on its behalf by:





Dr M S Sandhu - Director


OMNIGEN BIODATA LTD (REGISTERED NUMBER: 10565653)

Notes to the Financial Statements
for the Year Ended 31 December 2023

1. Statutory information

Omnigen Biodata Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Development costs are being amortised evenly over their estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on cost and 15% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research is written off in the year in which it is incurred.

Expenditure on development is capitalised and amortised once the product/service is available for use.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

OMNIGEN BIODATA LTD (REGISTERED NUMBER: 10565653)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

2. Accounting policies - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. Employees and directors

The average number of employees during the year was 19 (2022 - 12 ) .

4. Intangible fixed assets
Other
intangible
assets
£   
Cost
At 1 January 2023 2,208,006
Additions 1,328,272
At 31 December 2023 3,536,278
Amortisation
At 1 January 2023 188,521
Charge for year 220,800
At 31 December 2023 409,321
Net book value
At 31 December 2023 3,126,957
At 31 December 2022 2,019,485

5. Tangible fixed assets
Fixtures
and Computer
fittings equipment Totals
£    £    £   
Cost
At 1 January 2023 19,255 113,413 132,668
Additions 51,008 1,385 52,393
At 31 December 2023 70,263 114,798 185,061
Depreciation
At 1 January 2023 11,553 95,224 106,777
Charge for year 10,539 7,879 18,418
At 31 December 2023 22,092 103,103 125,195
Net book value
At 31 December 2023 48,171 11,695 59,866
At 31 December 2022 7,702 18,189 25,891

OMNIGEN BIODATA LTD (REGISTERED NUMBER: 10565653)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

6. Debtors: amounts falling due within one year
31/12/23 31/12/22
£    £   
Trade debtors 575,330 661,124
Other debtors 437,531 266,098
1,012,861 927,222

7. Creditors: amounts falling due within one year
31/12/23 31/12/22
£    £   
Bank loans and overdrafts 164,800 93,333
Trade creditors 261,820 42,637
Taxation and social security 44,411 39,893
Other creditors 35,816 690,826
506,847 866,689

8. Creditors: amounts falling due after more than one year
31/12/23 31/12/22
£    £   
Other creditors 20,833 30,833